Effect of Memantine Combination Therapy on Symptoms in Patients With Moderate-To-Severe Depressive Disorder: Randomized, Double-Blind, Placebo-Controlled Study

Effect of Memantine Combination Therapy on Symptoms in Patients With Moderate-To-Severe Depressive Disorder: Randomized, Double-Blind, Placebo-Controlled Study Publisher Pubmed

Amidfar M¹ ; Khiabany M² ; Kohi A² ; Salardini E² ; Arbabi M² ; Roohi Azizi M¹ ; Zarrindast MR¹ ; Mohammadinejad P² ; Zeinoddini A² ; Akhondzadeh S²

Show Affiliations

1. Department of Neuroscience, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
2. Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran

Source: Journal of Clinical Pharmacy and Therapeutics Published:2017

Abstract

What is known and objective: Current treatments for depressive disorders are far from optimum. This study was planned to evaluate possible antidepressant effects and safety of memantine, a selective N-methyl-d-aspartate receptor antagonist, in humans. Methods: Sixty-six outpatients with the diagnosis of moderate-to-severe major depressive disorder, based on DSM-V diagnostic criteria, were recruited to participate in a parallel, randomized, controlled trial. Sixty-two participants completed 6 weeks of treatment with either memantine (20 mg/day) plus sertraline (200 mg/day) or placebo plus sertraline (200 mg/day). Patients were evaluated using the Hamilton Depression Rating Scale (HDRS) at baseline and at weeks 2, 4 and 6. Comparison of treatment efficacy in improving depressive symptoms between the two groups was the principal outcome measure. Results and discussion: A repeated-measures analysis demonstrated significant time × treatment interaction on HDRS score [F (2·09, 125·67) = 5·09, P = 0·007]. Significantly greater improvement was seen at all three follow-up sessions as well as significantly greater response rates at weeks 4 and 6 (P = 0·018 and P < 0·001, respectively) in the memantine group. Significantly more early improvers and more rapid response to treatment were observed in the memantine group (P = 0·001 and P < 0·001, respectively). A significant reduction was observed in HDRS score from baseline to the study endpoint in both memantine (P < 0·001, Cohen's d = 12·71) and placebo groups (P < 0·001, Cohen's d = 5·13). No serious adverse event occurred. No significantly greater remission rate was seen in the adjunctive memantine therapy. What is new and conclusion: A 6-week course of treatment with memantine as adjunct to sertraline showed a favourable safety and efficacy profile in patients with major depressive disorder. Nonetheless, larger controlled studies of longer duration are necessary to assess long-term safety, efficacy and optimal dosing. © 2016 John Wiley & Sons Ltd

Related Docs

View other Related Docs

1. Riluzole Combination Therapy for Moderate-To-Severe Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Psychiatric Research (2016)

2. Agmatine Enhances the Antidepressant-Like Effect of Lithium in Mouse Forced Swimming Test Through Nmda Pathway, Biomedicine and Pharmacotherapy (2017)

3. Effectiveness of Memantine on Depression-Like Behavior, Memory Deficits and Brain Mrna Levels of Bdnf and Trkb in Rats Subjected to Repeated Unpredictable Stress, Pharmacological Reports (2018)

4. Ketamine and Other Glutamate Receptor Modulating Agents for Treatment-Resistant Depression: A Systematic Review of Randomized Controlled Trials, Iranian Journal of Psychiatry (2022)

5. Does Oral Administration of Ketamine Accelerate Response to Treatment in Major Depressive Disorder? Results of a Double-Blind Controlled Trial, Journal of Affective Disorders (2018)

6. Celecoxib for the Treatment of Mild-To-Moderate Depression Due to Acute Brucellosis: A Double-Blind, Placebo-Controlled, Randomized Trial, Journal of Clinical Pharmacy and Therapeutics (2015)

7. Simvastatin As an Adjuvant Therapy to Fluoxetine in Patients With Moderate to Severe Major Depression: A Double-Blind Placebo-Controlled Trial, Journal of Psychopharmacology (2015)

8. L-Carnosine Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Affective Disorders (2020)

Experts (# of related papers)

View all Related Experts

Shahin Akhondzadeh Basti (48)

Ahmad Reza Dehpour (11)

Style	Citing Format
MLA	Amidfar M, et al.. "Effect of Memantine Combination Therapy on Symptoms in Patients With Moderate-To-Severe Depressive Disorder: Randomized, Double-Blind, Placebo-Controlled Study." Journal of Clinical Pharmacy and Therapeutics, vol. 42, no. 1, 2017, pp. 44-50.
APA	Amidfar M, Khiabany M, Kohi A, Salardini E, Arbabi M, Roohi Azizi M, Zarrindast MR, Mohammadinejad P, Zeinoddini A, Akhondzadeh S (2017). Effect of Memantine Combination Therapy on Symptoms in Patients With Moderate-To-Severe Depressive Disorder: Randomized, Double-Blind, Placebo-Controlled Study. Journal of Clinical Pharmacy and Therapeutics, 42(1), 44-50.
Chicago	Amidfar M, Khiabany M, Kohi A, Salardini E, Arbabi M, Roohi Azizi M, Zarrindast MR, Mohammadinejad P, Zeinoddini A, Akhondzadeh S. "Effect of Memantine Combination Therapy on Symptoms in Patients With Moderate-To-Severe Depressive Disorder: Randomized, Double-Blind, Placebo-Controlled Study." Journal of Clinical Pharmacy and Therapeutics 42, no. 1 (2017): 44-50.
Harvard	Amidfar M et al. (2017) 'Effect of Memantine Combination Therapy on Symptoms in Patients With Moderate-To-Severe Depressive Disorder: Randomized, Double-Blind, Placebo-Controlled Study', Journal of Clinical Pharmacy and Therapeutics, 42(1), pp. 44-50.
Vancouver	Amidfar M, Khiabany M, Kohi A, Salardini E, Arbabi M, Roohi Azizi M, et al.. Effect of Memantine Combination Therapy on Symptoms in Patients With Moderate-To-Severe Depressive Disorder: Randomized, Double-Blind, Placebo-Controlled Study. Journal of Clinical Pharmacy and Therapeutics. 2017;42(1):44-50.
BibTex	@article{ author = {Amidfar M and Khiabany M and Kohi A and Salardini E and Arbabi M and Roohi Azizi M and Zarrindast MR and Mohammadinejad P and Zeinoddini A and Akhondzadeh S}, title = {Effect of Memantine Combination Therapy on Symptoms in Patients With Moderate-To-Severe Depressive Disorder: Randomized, Double-Blind, Placebo-Controlled Study}, journal = {Journal of Clinical Pharmacy and Therapeutics}, volume = {42}, number = {1}, pages = {44-50}, year = {2017} }
RIS	TY - JOUR AU - Amidfar M AU - Khiabany M AU - Kohi A AU - Salardini E AU - Arbabi M AU - Roohi Azizi M AU - Zarrindast MR AU - Mohammadinejad P AU - Zeinoddini A AU - Akhondzadeh S TI - Effect of Memantine Combination Therapy on Symptoms in Patients With Moderate-To-Severe Depressive Disorder: Randomized, Double-Blind, Placebo-Controlled Study JO - Journal of Clinical Pharmacy and Therapeutics VL - 42 IS - 1 SP - 44 EP - 50 PY - 2017 ER -

Style

Citing Format

MLA

Amidfar M, et al.. "Effect of Memantine Combination Therapy on Symptoms in Patients With Moderate-To-Severe Depressive Disorder: Randomized, Double-Blind, Placebo-Controlled Study." Journal of Clinical Pharmacy and Therapeutics, vol. 42, no. 1, 2017, pp. 44-50.

APA

Amidfar M, Khiabany M, Kohi A, Salardini E, Arbabi M, Roohi Azizi M, Zarrindast MR, Mohammadinejad P, Zeinoddini A, Akhondzadeh S (2017). Effect of Memantine Combination Therapy on Symptoms in Patients With Moderate-To-Severe Depressive Disorder: Randomized, Double-Blind, Placebo-Controlled Study. Journal of Clinical Pharmacy and Therapeutics, 42(1), 44-50.

Chicago

Amidfar M, Khiabany M, Kohi A, Salardini E, Arbabi M, Roohi Azizi M, Zarrindast MR, Mohammadinejad P, Zeinoddini A, Akhondzadeh S. "Effect of Memantine Combination Therapy on Symptoms in Patients With Moderate-To-Severe Depressive Disorder: Randomized, Double-Blind, Placebo-Controlled Study." Journal of Clinical Pharmacy and Therapeutics 42, no. 1 (2017): 44-50.

Harvard

Amidfar M et al. (2017) 'Effect of Memantine Combination Therapy on Symptoms in Patients With Moderate-To-Severe Depressive Disorder: Randomized, Double-Blind, Placebo-Controlled Study', Journal of Clinical Pharmacy and Therapeutics, 42(1), pp. 44-50.

Vancouver

Amidfar M, Khiabany M, Kohi A, Salardini E, Arbabi M, Roohi Azizi M, et al.. Effect of Memantine Combination Therapy on Symptoms in Patients With Moderate-To-Severe Depressive Disorder: Randomized, Double-Blind, Placebo-Controlled Study. Journal of Clinical Pharmacy and Therapeutics. 2017;42(1):44-50.

BibTex

@article{ author = {Amidfar M and Khiabany M and Kohi A and Salardini E and Arbabi M and Roohi Azizi M and Zarrindast MR and Mohammadinejad P and Zeinoddini A and Akhondzadeh S}, title = {Effect of Memantine Combination Therapy on Symptoms in Patients With Moderate-To-Severe Depressive Disorder: Randomized, Double-Blind, Placebo-Controlled Study}, journal = {Journal of Clinical Pharmacy and Therapeutics}, volume = {42}, number = {1}, pages = {44-50}, year = {2017} }

RIS

TY - JOUR
AU - Amidfar M
AU - Khiabany M
AU - Kohi A
AU - Salardini E
AU - Arbabi M
AU - Roohi Azizi M
AU - Zarrindast MR
AU - Mohammadinejad P
AU - Zeinoddini A
AU - Akhondzadeh S
TI - Effect of Memantine Combination Therapy on Symptoms in Patients With Moderate-To-Severe Depressive Disorder: Randomized, Double-Blind, Placebo-Controlled Study
JO - Journal of Clinical Pharmacy and Therapeutics
VL - 42
IS - 1
SP - 44
EP - 50
PY - 2017
ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract